title: Cost and utilization impact of a clinical pathway for patients undergoing pancreaticoduodenectomy.
abstract: BACKGROUND
  When implemented in several common surgical procedures, clinical pathways have been reported to reduce costs and resource utilization, while maintaining or improving patient care. However, there is little data to support their use in more complex surgery. The objective of this study was to determine the effects of clinical pathway implementation in patients undergoing elective pancreaticoduodenectomy (PD) on cost and resource utilization.
  
  
  METHODS
  Outcome data from before and after the development of a clinical pathway were analyzed. The clinical pathway standardized the preoperative outpatient care, critical care, and postoperative floor care of patients who underwent PD. An independent department determined total costs for each patient, which included all hospital and physician costs, in a blinded review. Outcomes that were examined included perioperative mortality, postoperative morbidity, length of stay, readmissions, and postoperative clinic visits.
  
  
  RESULTS
  From January, 1996 to December, 1998, 148 consecutive patients underwent PD or total pancreatectomy; 68 before pathway development (PrePath) and 80 after pathway implementation (PostPath). There were no significant differences in patient demographics, comorbid conditions, underlying diagnosis, or use of neoadjuvant therapy between the two groups. Mean total costs were significantly reduced in PostPath patients compared with PrePath patients ($36,627 vs. $47,515; P = .003). Similarly, mean length of hospital stay was also significantly reduced in PostPath patients (13.5 vs. 16.4 days; P = .001). The total cost differences could not be attributed solely to differences in room and board costs. Cost and length-of-stay differences remained when outliers were excluded from the analysis. Despite these findings, there were no significant differences between PrePath and PostPath patients in terms of perioperative mortality (3% vs. 1%), readmissions within 1 month of discharge (15% vs. 11%), or mean number of clinic visits within 90 days of discharge (3.3 vs. 3.4 visits).
  
  
  CONCLUSIONS
  The establishment of a clinical pathway for PD patients dramatically reduced costs and resource utilization without any apparent detrimental effect on quality of patient care. These findings support the implementation of clinical pathways for PD patients, as well as investigation into pathway care for other complex surgical procedures.
authors.affiliation: Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.
authors.forename: G A
authors.initials: GA
authors.lastname: Porter
authors.forename: P W
authors.initials: PW
authors.lastname: Pisters
authors.forename: C
authors.initials: C
authors.lastname: Mansyur
authors.forename: A
authors.initials: A
authors.lastname: Bisanz
authors.forename: K
authors.initials: K
authors.lastname: Reyna
authors.forename: P
authors.initials: P
authors.lastname: Stanford
authors.forename: J E
authors.initials: JE
authors.lastname: Lee
authors.forename: D B
authors.initials: DB
authors.lastname: Evans
mesh_terms: D000368:Aged; D001650:Bile Duct Neoplasms / Q000601:surgery; D017046:Cost Savings; D003362:Cost-Benefit Analysis; D019091:Critical Pathways; D004379:Duodenal Neoplasms / Q000601:surgery; D005260:Female; D006296:Health Services / Q000191:economics / Q000706:statistics & numerical data*; D017721:Hospital Costs; D006801:Humans; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D010180:Pancreatectomy / Q000191:economics*; D010190:Pancreatic Neoplasms / Q000601:surgery; D016577:Pancreaticoduodenectomy / Q000191:economics*; D010351:Patient Discharge; D011446:Prospective Studies